Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients

Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients

PD-1 pathway blockade has been shown to promote proatherogenic T-cell responses and destabilization of atherosclerotic plaques. Moreover, preclinical evidence suggests a potential synergy of antiplatelet drugs with immune checkpoint inhibitors (ICIs). We conducted an analysis within a prospective ob...

Full description

Bibliographic Details
Main Authors: Federico Nichetti, Francesca Ligorio, Emma Zattarin, Diego Signorelli, Arsela Prelaj, Claudia Proto, Giulia Galli, Antonio Marra, Giulia Apollonio, Luca Porcu, Filippo de Braud, Giuseppe Lo Russo, Roberto Ferrara, Marina Chiara Garassino
Format: Article
Language:English
Published: MDPI AG 2019-12-01
Series:Cancers
Subjects:
immunotherapy
immune checkpoint inhibitors
thromboprophylaxis
aspirin
thromboembolic events
non-small cell lung cancer
Online Access:https://www.mdpi.com/2072-6694/12/1/67

Internet

https://www.mdpi.com/2072-6694/12/1/67

Similar Items